UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,311	12/12/2005	Meena Augustus	357074.00006	4638
74549 <b>Saul Ewing</b> LLI	7590 11/26/201 <sup>1</sup> P (Baltimore)	EXAMINER		
Attn: Patent Spo	ecialist	KIM, YOUNG J		
500 East Pratt S 9th Floor	orreet	ART UNIT	PAPER NUMBER	
BALTIMORE,	MD 21202	1637		
			MAIL DATE	DELIVERY MODE
			11/26/2010	PAPER

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/540,311	AUGUSTUS ET AL.		
Examiner	Art Unit		
Young J. Kim	1637		

	Young J. Kim	1637	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>15 November 2010</u> FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.	
1.  The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apple for Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of a replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
<ul> <li>a) The period for reply expires 3 months from the mailing date</li> <li>b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire is Examiner Note: If box 1 is checked, check either box (a) or (a)</li> </ul>	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	g date of the final rejection	n.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07( Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	f). on which the petition under 37 CFR 1.1 tension and the corresponding amount of shortened statutory period for reply origithan three months after the mailing dat	36(a) and the appropriat of the fee. The appropriat nally set in the final Offic	e extension fee ate extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any externation Notice of Appeal has been filed, any reply must be filed water MAMENDMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. X The proposed amendment(s) filed after a final rejection, I	out prior to the data of filing a brief	will not be entered be	001100
(a) ☑ They raise new issues that would require further colline (b) ☑ They raise the issue of new matter (see NOTE belo	nsideration and/or search (see NOTw);	ΓE below);	
(c) They are not deemed to place the application in bet appeal; and/or			ne issues for
(d) They present additional claims without canceling a NOTE: See Continuation Sheet. (See 37 CFR 1.1		ected claims.	
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (I	PTOL-324).
5. Applicant's reply has overcome the following rejection(s)	:	•	•
6. Newly proposed or amended claim(s) would be al non-allowable claim(s).		•	-
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: 66 and 70.		l be entered and an e:	xplanation of
Claim(s) rejected: <u>16-18,28-30,65 and 67-69</u> . Claim(s) withdrawn from consideration: <u>1-15,19-27 and 3</u>	<i>1-59</i> .		
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fail:	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.
11.  The request for reconsideration has been considered bu	t does NOT place the application in	condition for allowan	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s). 013. Other:	(PTO/SB/08) Paper No(s)		
	/Young J Kim/		
	Primary Examiner, Art U	nit 1637	

Continuation of 3. NOTE: Claim 16, step (a) has been amended from the phrase, "determining a cell the copy number of at least one gene," to the phrase, "determining a cell copy number of at least one gene..." The latter-amended phrase is different from the claim as previously recited because the latter phrase no longer determines the copy number of the gene, but rather the copy number of a cell. The two are not synonymous. Such amendment, therefore raises new issues of indefiniteness, new matter, and prior art issues. Claim 28 has been amended from the phrase, "wherein said expression IS increased copy number of said gene," to the phrase, "said expression HAS increased copy number of said gene." The former, previously prosecuted claim defines the expression as being increased copy number of a gene, whereas the latter, amended phrase does not. The latter-amended phrase recites that the expression "has" increased the copy number of said gene. A gene copy cannot be increased by an expression. Rather, an expression is increased by either an increase in the actual gene copy or by other biochemical mechanisms. However, an increase in expression cannot increase the copy number of the gene. This amendment raises new matter, indefiniteness, and possible prior art issues (i.e., if the expression level of TRIP13 is being analyzed rather than the gene copy number, then the previous prior art of record may have to be reinstituted. Claims 17, 18, 29, 30, 67, and 69 are dependent on either claim 16 or 28 and thus will have the same issue by way of their dependency.